Clinical Trial Update: CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy [Phase 1, Phase 2]

View source ↗

Summary

Preliminary update on CD19-directed CAR T cell therapy for relapsed/refractory B cell malignancies across Phase 1 and Phase 2 trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• CD19-directed CAR T cells therapy (CD19-directed CAR T cells)

Snippet

Sponsor: Shanghai Tongji Hospital, Tongji University School of Medicine | Conditions: Leukemia, Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN